438 related articles for article (PubMed ID: 26819195)
1. Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
Reyes-Soffer G; Moon B; Hernandez-Ono A; Dionizovik-Dimanovski M; Jimenez J; Obunike J; Thomas T; Ngai C; Fontanez N; Donovan DS; Karmally W; Holleran S; Ramakrishnan R; Mittleman RS; Ginsberg HN
Sci Transl Med; 2016 Jan; 8(323):323ra12. PubMed ID: 26819195
[TBL] [Abstract][Full Text] [Related]
2. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
Zulewski H; Ninnis R; Miserez AR; Baumstark MW; Keller U
J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
[TBL] [Abstract][Full Text] [Related]
3. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
4. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men.
Millar JS; Lichtenstein AH; Cuchel M; Dolnikowski GG; Hachey DL; Cohn JS; Schaefer EJ
J Lipid Res; 1995 Jun; 36(6):1155-67. PubMed ID: 7665994
[TBL] [Abstract][Full Text] [Related]
5. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia.
Hooper AJ; Heeks L; Robertson K; Champain D; Hua J; Song S; Parhofer KG; Barrett PH; van Bockxmeer FM; Burnett JR
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1484-90. PubMed ID: 26323024
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
Packard CJ; Demant T; Stewart JP; Bedford D; Caslake MJ; Schwertfeger G; Bedynek A; Shepherd J; Seidel D
J Lipid Res; 2000 Feb; 41(2):305-18. PubMed ID: 10681415
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
10. Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity.
Pont F; Duvillard L; Florentin E; Gambert P; Vergès B
Arterioscler Thromb Vasc Biol; 2002 Oct; 22(10):1726-32. PubMed ID: 12377756
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutations.
Ooi EM; Russell BS; Olson E; Sun SZ; Diffenderfer MR; Lichtenstein AH; Keilson L; Barrett PH; Schaefer EJ; Sprecher DL
Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):459-66. PubMed ID: 22095987
[TBL] [Abstract][Full Text] [Related]
12. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
Arad Y; Ramakrishnan R; Ginsberg HN
J Lipid Res; 1990 Apr; 31(4):567-82. PubMed ID: 2351867
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
14. Decreased production and increased catabolism of apolipoprotein B-100 in apolipoprotein B-67/B-100 heterozygotes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Ordovas JM; Schaefer EJ
Arterioscler Thromb Vasc Biol; 1997 May; 17(5):881-8. PubMed ID: 9157951
[TBL] [Abstract][Full Text] [Related]
15. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
[TBL] [Abstract][Full Text] [Related]
16. Production of apolipoprotein B-67 in apolipoprotein B-67/B-100 heterozygotes: technical problems associated with leucine contamination in stable isotope studies.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Ordovas JM; Schaefer EJ
J Lipid Res; 1997 Aug; 38(8):1535-43. PubMed ID: 9300775
[TBL] [Abstract][Full Text] [Related]
17. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.
Vergès B; Florentin E; Baillot-Rudoni S; Monier S; Petit JM; Rageot D; Gambert P; Duvillard L
Diabetologia; 2008 Aug; 51(8):1382-90. PubMed ID: 18535816
[TBL] [Abstract][Full Text] [Related]
18. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
[TBL] [Abstract][Full Text] [Related]
19. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
Gaw A; Packard CJ; Lindsay GM; Griffin BA; Caslake MJ; Lorimer AR; Shepherd J
J Lipid Res; 1995 Jan; 36(1):158-71. PubMed ID: 7706941
[TBL] [Abstract][Full Text] [Related]
20. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
